Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$80.41
-1.6%
$74.90
$61.24
$83.43
$249.40B0.375.14 million shs358,342 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$723.95
-0.4%
$743.84
$623.78
$942.35
$684.72B0.474.12 million shs367,822 shs
Novartis AG stock logo
NVS
Novartis
$128.24
-1.1%
$121.25
$96.06
$130.46
$270.94B0.631.91 million shs166,023 shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.57
-1.3%
$24.85
$20.92
$30.43
$139.38B0.5544.70 million shs7.03 million shs
Roche Holding AG stock logo
RHHBY
Roche
$42.34
-1.5%
$40.21
$34.10
$44.31
$269.42B0.472.24 million shs206,879 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.00%+2.25%+11.07%+11.90%-1.63%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-0.83%+16.19%-6.11%-19.54%
Novartis AG stock logo
NVS
Novartis
0.00%+2.65%+11.09%+9.96%+11.24%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+0.47%+1.16%+3.71%-12.97%
Roche Holding AG stock logo
RHHBY
Roche
0.00%+5.47%+12.48%+5.26%+6.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$80.41
-1.6%
$74.90
$61.24
$83.43
$249.40B0.375.14 million shs358,342 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$723.95
-0.4%
$743.84
$623.78
$942.35
$684.72B0.474.12 million shs367,822 shs
Novartis AG stock logo
NVS
Novartis
$128.24
-1.1%
$121.25
$96.06
$130.46
$270.94B0.631.91 million shs166,023 shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.57
-1.3%
$24.85
$20.92
$30.43
$139.38B0.5544.70 million shs7.03 million shs
Roche Holding AG stock logo
RHHBY
Roche
$42.34
-1.5%
$40.21
$34.10
$44.31
$269.42B0.472.24 million shs206,879 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.00%+2.25%+11.07%+11.90%-1.63%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-0.83%+16.19%-6.11%-19.54%
Novartis AG stock logo
NVS
Novartis
0.00%+2.65%+11.09%+9.96%+11.24%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+0.47%+1.16%+3.71%-12.97%
Roche Holding AG stock logo
RHHBY
Roche
0.00%+5.47%+12.48%+5.26%+6.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.80
Moderate Buy$86.006.96% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.70
Moderate Buy$950.1731.25% Upside
Novartis AG stock logo
NVS
Novartis
2.11
Hold$124.33-3.05% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.39
Hold$28.1214.45% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.57
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest LLY, AZN, NVS, PFE, and RHHBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeReduceHold$675.00 ➝ $700.00
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate SellHold
8/21/2025
Novartis AG stock logo
NVS
Novartis
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformNeutral$700.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/14/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DZ Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/13/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$975.00 ➝ $825.00
8/13/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$942.00 ➝ $875.00
8/11/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$1,010.00 ➝ $900.00
8/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$1,050.00 ➝ $895.00
8/8/2025
Novartis AG stock logo
NVS
Novartis
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderweightEqual Weight$123.00
(Data available from 9/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.61$6.19 per share12.98$13.18 per share6.10
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.21$14.17 per share51.09$15.03 per share48.17
Novartis AG stock logo
NVS
Novartis
$50.32B5.38$10.58 per share12.12$21.59 per share5.94
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.20$4.31 per share5.70$15.62 per share1.57
Roche Holding AG stock logo
RHHBY
Roche
$68.73B3.92$3.25 per share13.02$6.46 per share6.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.6630.2316.081.5014.68%32.84%12.87%11/11/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3047.2823.261.0125.91%92.72%16.89%10/29/2025 (Estimated)
Novartis AG stock logo
NVS
Novartis
$11.94B$6.8718.6714.561.8125.64%41.08%16.83%11/4/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.048.110.8816.84%21.42%9.12%11/4/2025 (Estimated)
Roche Holding AG stock logo
RHHBY
Roche
$9.40BN/A0.0014.112.37N/AN/AN/AN/A

Latest LLY, AZN, NVS, PFE, and RHHBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
7/29/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.09$1.09N/A$0.79$14.08 billion$14.46 billion
7/17/2025Q2 2025
Novartis AG stock logo
NVS
Novartis
$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.011.26%N/A37.97%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.83%N/A39.22%11 Years
Novartis AG stock logo
NVS
Novartis
$2.602.03%N/A37.85%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.00%N/A91.49%16 Years
Roche Holding AG stock logo
RHHBY
Roche
$0.872.05%N/AN/AN/A

Latest LLY, AZN, NVS, PFE, and RHHBY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
7/29/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$0.50502%8/8/20258/8/20259/8/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.55
0.86
0.67
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Novartis AG stock logo
NVS
Novartis
0.53
0.82
0.62
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85
Roche Holding AG stock logo
RHHBY
Roche
0.85
1.48
1.20

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Roche Holding AG stock logo
RHHBY
Roche
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.13 millionOptionable
Novartis AG stock logo
NVS
Novartis
75,8832.11 billion2.11 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,2496.36 billionN/ANot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$80.40 -1.30 (-1.59%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$723.95 -3.26 (-0.45%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novartis stock logo

Novartis NYSE:NVS

$128.24 -1.49 (-1.15%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer stock logo

Pfizer NYSE:PFE

$24.57 -0.31 (-1.26%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Roche stock logo

Roche OTCMKTS:RHHBY

$42.34 -0.66 (-1.53%)
As of 09:47 AM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.